Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to...
-
Announced Expansion of Briquilimab (formerly known as JSP191) Development Strategy to Include Chronic Spontaneous UrticariaPresentation of Key Briquilimab Clinical Data, Including Initial Results in...
-
REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...
-
Both Fanconi Anemia patients treated with briquilimab successfully engrafted with neutrophil engraftment within 11 days100% total donor chimerism was achieved through six months for the first patient...
-
Oral Presentation, Abstract #59: 12 out of 12 AML in complete remission patients with full 1-year follow-up achieved successful neutrophil engraftment at a median of 19 days after conditioning with...
-
First two sickle cell disease participants have achieved 100% donor myeloid chimerism through 100 days follow-upThird sickle cell disease participant has now achieved 100% donor myeloid chimerism...
-
REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...
-
REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...
-
REDWOOD CITY, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...
-
REDWOOD CITY, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit...